Searched for
FOPE PHARMA LOBBY
Drug, medtech companies fear GST changes may squeeze fundsPharma and medtech sectors are concerned about upcoming Goods and Services Tax changes. They anticipate higher operating costs and working ...- Stricter shelf life rule a bitter pill to swallow for pharma companiesA new regulation by the CDSCO mandates that exported drugs must have at least 60% shelf life remaining, causing significant losses to the I...
- Pharma companies may lose licence if drugs fail testsThe health ministry is considering strict actions, including immediate license suspensions, for drugmakers producing substandard drugs. Thi...
- Russia-Ukraine war: Indian pharma firm caught in crossfire, lobby seeks PM Modi’s helpAn Indian pharmaceutical company, Kusum Healthcare, operating in Ukraine, suffered significant damages after a warehouse was reportedly str...
- Pharma companies must file compliance strategyDrugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and medium manufact...
- Government extends deadline for small drug companies to comply with revised schedule M standardsThe government is expected to extend the deadline for small drug companies to comply with the revised Schedule M standards until December 3...
- Pharma companies may get time till December to comply with schedule M normsThe govt may extend the deadline for drug manufacturers to comply with revised Schedule M standards until December 2025. A final notificati...
- Health minister seeks legal view on final schedule M draft noticeThe health ministry has sought a legal opinion on extending the deadline for MSMEs to comply with revised Schedule M standards. The final d...
- Pharma lobby seeks 2-year extension of schedule M deadlinePharma lobby group FOPE has requested the government to extend the compliance deadline for the revised Schedule M till December 31, 2026. T...
- Centre may decide on rollout of Schedule M by next weekThe government is set to decide on implementing the revised Schedule M for pharmaceutical products by next week. While pharma groups have r...
- Pharma companies seek more time to implement revised norms on manufacturing practicesSchedule M of the Drugs and Cosmetics Rules, 1945 prescribes the good manufacturing practices (GMP) for pharmaceutical products, such as a ...
- Pharma industry seeks relief from price cap rule for cheap drugsIndia’s FoPE seeks a 10-year exemption for patented and low-cost drugs from price controls. Requests include DPCO and 12% GST adjustments d...
- Panel to examine if nutraceuticals can be produced within drug unitIn a significant development, a five-member expert committee has been appointed to assess the feasibility of allowing the manufacturing of ...
- Lens on cos making drugs, supplements in same facility: Pharma body hopeful of a rethink on govt actionIn a recent diktat, the government said action will be taken against pharma units that are flouting the norms by manufacturing nutraceutica...
- FOPE urges pause on NPPA notice, citing potential losses for pharma industryFOPE said that the manufactures follow the rules as laid down in the DPCO, 2013. At the same time, manufacturers look to NPPA to fix the pr...
- Coronavirus pandemic threatens to cut pharmaceutical industry’s lifelineRaw materials from China are used in making antibiotics, paracetamol, and diabetes and cardiovascular drugs, among others. Companies includ...
- Delhi HC seeks government view on validity of drug companies' licencesThe HC asked the government whether it needed to consider the validity of licences held by pharma companies producing the combination drugs...
Load More
